nct_id,title,phase,status,study_type,conditions,interventions,molecular_targets,sponsor,collaborators,enrollment_count,start_date,completion_date,locations,needs_review,source_url
NCT00034216,Biospecimen Acquisition From Human Subjects,,Recruiting,Observational,Prostate Cancer; Breast Cancer; Colon Cancer; Lung Cancer; Liver Cancer,,,National Cancer Institute (NCI),,1750,2002-07-16,,United States,No,https://clinicaltrials.gov/study/NCT00034216
NCT00756665,Canary Prostate Active Surveillance Study,,Recruiting,Observational,Prostatic Neoplasms,,,University of Washington,Canary Foundation; Early Detection Research Network,3000,2008-07-05,2032-09-05,Canada; United States,No,https://clinicaltrials.gov/study/NCT00756665
NCT00923221,Collection of Blood From Patients With Prostate Cancer,,Recruiting,Observational,Cancer Of Prostate; Prostate Cancer; Prostatic Neoplasms; Metastatic Prostate Cancer; Prostate,,,National Cancer Institute (NCI),,1000,2007-02-28,,United States,No,https://clinicaltrials.gov/study/NCT00923221
NCT01961713,Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy,,Recruiting,Observational,Prostate Cancer,,,Massachusetts General Hospital,Prostate Cancer Foundation Clinical Research Consortium,200,2010-04-05,2025-12-05,United States,No,https://clinicaltrials.gov/study/NCT01961713
NCT02000089,The Cancer of the Pancreas Screening-5 CAPS5)Study,Phase 3,Recruiting,Interventional,Pancreas Cancer; Peutz-Jeghers Syndrome (PJS); Gene Mutation; Germline Mutation Carrier; Lynch Syndrome,Secretin; MRI; Tumor marker gene test with CA19-9,,Johns Hopkins University,National Cancer Institute (NCI); National Institutes of Health (NIH); American Association for Cancer Research,9000,2014-01-06,2029-06-05,United States,No,https://clinicaltrials.gov/study/NCT02000089
NCT02302742,"PROspective Evaluation of GErmline Mutations, Cancer Outcome and Tissue Biomarkers: A Registry for Patients With Triple Negative Breast Cancer and Germline Mutations",,Recruiting,Observational,Breast Cancer; Hereditary Breast and Ovarian Cancer,,,University of Kansas Medical Center,,1500,2011-03-22,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT02302742
NCT02775461,Pancreas Disease and High Risk Registry,,Recruiting,Observational,Pancreas Cancer; Pancreatitis; Chronic Pancreatitis; Pancreatic Cyst; Family History of Pancreas Cancer; Genetic Mutations,,,Icahn School of Medicine at Mount Sinai,,1116,2013-03-01,2033-11-05,United States,No,https://clinicaltrials.gov/study/NCT02775461
NCT02997709,Collection and Measurement of Blood and Imaging Biomarkers in Patients Undergoing Standard Primary and Postoperative Radiotherapy for Prostatic Neoplasms - The Miami CoMBINe Trial,,Recruiting,Observational,Prostate Cancer,,,University of Miami,Bankhead-Coley Florida Biomedical Research Program,144,2016-06-24,2032-06-05,United States,No,https://clinicaltrials.gov/study/NCT02997709
NCT03127631,The Role of Androgen Deprivation Therapy In Cardiovascular Disease - A Longitudinal Prostate Cancer Study (RADICAL PC1) & A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICAL PC2),Not Applicable,Recruiting,Interventional,Prostate Cancer; Cardiovascular Disease,"Nutrition; Exercise; Smoking cessation; Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin); ACE inhibitor",,McMaster University,Prostate Cancer Canada; Canadian Cancer Society (CCS),6000,2015-10-21,2026-12-05,Australia; Brazil; Canada; Colombia; Israel; Turkey (Türkiye); United States,No,https://clinicaltrials.gov/study/NCT03127631
NCT03460977,"A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF 06821497 (MEVROMETOSTAT) IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)",Phase 1,Recruiting,Interventional,Metastatic Castration Resistant Prostate Cancer (mCRPC); Small Cell Lung Cancer (SCLC); Follicular Lymphoma (FL),Mervometostat (PF-06821497); Enzalutamide,,Pfizer,,433,2018-04-17,2029-03-14,Bulgaria; China; Japan; Poland; Russia; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT03460977
NCT03568630,A Longitudinal Cohort Study to Identify Clinical and Blood Markers of Early Pancreas Cancer,,Recruiting,Observational,"Diabetes Mellitus, Type 2; PreDiabetes; Pancreas Cyst; Chronic Pancreatitis; Genetic Predisposition to Disease; Inherited Disease",,,University of Nebraska,National Cancer Institute (NCI); Virginia Mason Hospital/Medical Center; VA Nebraska Western Iowa Health Care System,1250,2018-07-26,2028-07-05,United States,No,https://clinicaltrials.gov/study/NCT03568630
NCT03678025,Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer,Phase 3,Recruiting,Interventional,Castration Levels of Testosterone; Metastatic Prostatic Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8,Abiraterone; Bicalutamide; Degarelix; Docetaxel; Flutamide; Goserelin Acetate; Histrelin Acetate; Leuprolide Acetate; Nilutamide; Orchiectomy; Prednisone; Quality-of-Life Assessment; Radiation Therapy; Radical Prostatectomy; Triptorelin,,SWOG Cancer Research Network,National Cancer Institute (NCI),1273,2018-09-24,2031-10-01,Chile; Colombia; Mexico; Switzerland; United States,No,https://clinicaltrials.gov/study/NCT03678025
NCT03851445,LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study),Phase 2/Phase 3,Recruiting,Interventional,Previously Treated Non-Small Cell Lung Cancer,Screening Platform,,SWOG Cancer Research Network,National Cancer Institute (NCI),10000,2019-02-06,2029-01-28,United States,No,https://clinicaltrials.gov/study/NCT03851445
NCT03972657,A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression,Phase 1/Phase 2,Recruiting,Interventional,Metastatic Castration-Resistant Prostate Cancer (mCRPC); Clear Cell Renal Cell Carcinoma (ccRCC),REGN5678; Cemiplimab,,Regeneron Pharmaceuticals,,345,2019-08-12,2027-11-15,United States,No,https://clinicaltrials.gov/study/NCT03972657
NCT04038502,"An Open-label, Multicenter Phase II Study to Compare the Efficacy of Carboplatin as First-line Followed by Second-line Olaparib Versus Olaparib as First-line Followed by Second-line Carboplatin in the Treatment of Patients With Castration Resistant Prostate Cancer Containing Homologous Recombination Deficiency",Phase 2,Recruiting,Interventional,"Metastatic Castrate Resistant Prostate Cancer; BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2; RAD51B, RAD51C, RAD51D, or RAD54L Mutations",Carboplatin; Olaparib,,VA Office of Research and Development,,100,2019-10-01,2027-08-31,United States,No,https://clinicaltrials.gov/study/NCT04038502
NCT04145375,Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol,Phase 1/Phase 2,Enrolling by invitation,Interventional,mCRPC,ZEN003694; Enzalutamide,,Zenith Epigenetics,,40,2019-11-12,2026-12-31,United States,No,https://clinicaltrials.gov/study/NCT04145375
NCT04221542,"A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer",Phase 1,Recruiting,Interventional,Prostate Cancer,AMG 509; Abiraterone; Enzalutamide,,Amgen,BeiGene; BeOne (China only),479,2020-03-04,2032-03-21,Australia; China; Germany; Japan; Portugal; South Korea; Spain; Switzerland; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT04221542
NCT04254133,Genetic Information to Inform Treatment and Screening (GIFTS) Study for Prostate Cancer,,Enrolling by invitation,Observational,Prostate Carcinoma,Questionnaire; Biospecimen Collection; Genetic Testing; Genetic Counseling; Laboratory Biomarker Analysis,,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),1360,2018-11-30,2028-08-31,United States,No,https://clinicaltrials.gov/study/NCT04254133
NCT04314401,Cancer Moonshot Biobank Research Protocol,,Recruiting,Observational,Acute Myeloid Leukemia; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Clinical Stage IV Esophageal Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Esophageal Carcinoma; Fallopian Tube Carcinoma; Gastric Carcinoma; Hormone Receptor-Positive Breast Carcinoma; Invasive Breast Carcinoma; Lung Non-Small Cell Carcinoma; Lung Small Cell Carcinoma; Malignant Solid Neoplasm; Melanoma; Metastatic Prostate Carcinoma; Multiple Myeloma; Ovarian Carcinoma; Ovarian High Grade Serous Adenocarcinoma; Primary Peritoneal Carcinoma; Stage III Fallopian Tube Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8; Triple-Negative Breast Carcinoma,Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Medical Chart Review; Paracentesis; Positron Emission Tomography,,National Cancer Institute (NCI),,1600,2020-11-11,2027-04-30,Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT04314401
NCT04552509,Prospective Evaluation of TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer: Risk Stratified MonoTherapy Versus RADIOSURGERY Boost,Not Applicable,Recruiting,Interventional,Prostate Cancer,Stereotactic Body Radiotherapy,,"Linda Chan, MD",,167,2018-06-05,2026-12-01,United States,No,https://clinicaltrials.gov/study/NCT04552509
NCT04573231,"Evaluation of Prostate Specific Membrane Antigen (PSMA) in HER2-negative, Androgen Receptor (AR)-Positive Metastatic Breast Cancer With 18F-DCFPyL PSMA-based PET/CT",Phase 2,Recruiting,Interventional,Breast Cancer; HER2-negative Breast Cancer; Metastatic Breast Cancer,18F-DCFPyL,,"University of Wisconsin, Madison",,13,2021-05-24,2025-12-05,United States,No,https://clinicaltrials.gov/study/NCT04573231
NCT04704505,Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) (BAT-RAD Study),Phase 2,Recruiting,Interventional,Prostate Adenocarcinoma; Metastatic Prostate Adenocarcinoma; Castration-resistant,radium-223; Bipolar Androgen Therapy (BAT),,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Bayer,47,2022-04-28,2027-02-05,Brazil; United States,No,https://clinicaltrials.gov/study/NCT04704505
NCT04858334,"APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation",Phase 2,Recruiting,Interventional,Pancreatic Acinar Cell Carcinoma; Pancreatic Adenosquamous Carcinoma; Pancreatic Squamous Cell Carcinoma; Resectable Pancreatic Acinar Cell Carcinoma; Resectable Pancreatic Adenocarcinoma; Resectable Pancreatic Adenosquamous Carcinoma; Resectable Pancreatic Carcinoma,Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Olaparib; Placebo Administration,,National Cancer Institute (NCI),,152,2021-06-22,2027-10-31,Israel; Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT04858334
NCT04868604,A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer,Phase 1/Phase 2,Recruiting,Interventional,"Prostatic Neoplasms, Castration-Resistant",64Cu-SAR-bisPSMA; 67Cu-SAR-bisPSMA,,Clarity Pharmaceuticals Ltd,,54,2021-08-11,2026-09-05,Australia; United States,No,https://clinicaltrials.gov/study/NCT04868604
NCT04890613,Phase Ib Expansion Study of CX-5461 in Patients With Solid Tumours and BRCA2 and/or PALB2 Mutation,Phase 1,Recruiting,Interventional,Advanced Solid Tumor,CX-5461,,"Senhwa Biosciences, Inc.",,52,2021-09-08,2026-12-05,Canada; United States,No,https://clinicaltrials.gov/study/NCT04890613
NCT04898634,"A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer",Phase 1,Recruiting,Interventional,Prostatic Neoplasms,JNJ-78278343,,"Janssen Research & Development, LLC",,216,2021-07-13,2027-02-10,China; France; Japan; Netherlands; Spain; United States,No,https://clinicaltrials.gov/study/NCT04898634
NCT04945642,Phase 2 Study of High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for Intermediate and High Risk Localized Prostate Adenocarcinoma (HYDRA),Not Applicable,Recruiting,Interventional,Prostate Adenocarcinoma; Stage IIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8; Stage IIC Prostate Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IIIA Prostate Cancer AJCC v8; Stage IIIB Prostate Cancer AJCC v8; Stage IIIC Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8,High-Dose Rate Brachytherapy; Stereotactic Body Radiation Therapy,,Jonsson Comprehensive Cancer Center,,52,2021-08-20,2027-07-01,United States,No,https://clinicaltrials.gov/study/NCT04945642
NCT04946370,Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer,Phase 1/Phase 2,Recruiting,Interventional,Prostate Cancer,225Ac-J591; Pembrolizumab; Androgen receptor inhibitor; 68Ga-PSMA-11,,Weill Medical College of Cornell University,United States Department of Defense; Merck Sharp & Dohme LLC,76,2021-08-12,2029-12-05,United States,No,https://clinicaltrials.gov/study/NCT04946370
NCT04970056,Pancreatic Cancer Early Detection Consortium,,Recruiting,Observational,Pancreas Cancer; Pancreas Cyst; Pancreatic Ductal Adenocarcinoma; Genetic Predisposition,,,Arbor Research Collaborative for Health,,10000,2020-09-18,2030-12-31,Australia; Canada; Hungary; Iceland; Israel; Italy; Singapore; Spain; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04970056
NCT04986423,A Randomized Phase 2b Study of ZEN003694 in Combination With Enzalutamide Versus Enzalutamide Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer,Phase 2,Recruiting,Interventional,Metastatic Castration-Resistant Prostate Cancer,ZEN003694; Enzalutamide,,Zenith Epigenetics,"Astellas Pharma Inc; Newsoara Biopharma Co., Ltd.",200,2021-09-08,2026-06-05,China; United States,No,https://clinicaltrials.gov/study/NCT04986423
NCT04992728,Quantitative Diffusion MRI for Prostate Cancer Detection and Monitoring,,Recruiting,Observational,Prostate Cancer,Restricted Spectrum Magnetic Resonance Imagining,,"University of California, San Diego",,100,2021-11-02,2026-11-01,United States,No,https://clinicaltrials.gov/study/NCT04992728
NCT04995198,PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness,,Recruiting,Observational,Prostate Cancer,,,Prostate Cancer Clinical Trials Consortium,"Memorial Sloan Kettering Cancer Center; Fred Hutchinson Cancer Center; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Advancing Cancer Treatment, Inc.",500,2021-05-03,2036-02-26,United States,No,https://clinicaltrials.gov/study/NCT04995198
NCT05079698,"A Safety Study of Stereotactic Body Radiotherapy (SBRT) and 177Lu-PSMA617 for the Treatment of Hormone Sensitive, Oligometastatic Prostate Cancer",Phase 1,Recruiting,Interventional,Prostate Cancer,177Lu-PSMA-617; Stereotactic Body Radiotherapy (SBRT),,Memorial Sloan Kettering Cancer Center,Novartis Pharmaceuticals,27,2021-10-01,2026-10-05,United States,No,https://clinicaltrials.gov/study/NCT05079698
NCT05107674,"A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types",Phase 1,Recruiting,Interventional,"Ovarian Cancer, Epithelial; Gastric Cancer; GastroEsophageal Junction (GEJ) Cancer; Head and Neck Squamous Cell Carcinoma; Metastatic or Unresectable Melanoma; Non-small Cell Lung Cancer (NSCLC); Metastatic Castration-resistant Prostate Cancer (mCRPC); Malignant Pleural Mesothelioma (MPM); Triple Negative Breast Cancer (TNBC); Metastatic Urothelial Carcinoma; Cervical Cancer; Diffuse Large B Cell Lymphoma (DLBCL); Richter Transformation; Microsatellite Stable Colorectal Carcinoma",NX-1607; Paclitaxel,,"Nurix Therapeutics, Inc.",,345,2021-09-29,2028-02-28,United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05107674
NCT05129605,Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS),,Recruiting,Observational,Prostatic Neoplasm; Prostate Cancer; BRCA2 Mutation; BRCA1 Mutation; ATM Gene Mutation; MMR Mutation; Lynch Syndrome; Genetic Predisposition to Disease,Prostate cancer screening,,Massachusetts General Hospital,,400,2020-02-12,2040-12-05,United States,No,https://clinicaltrials.gov/study/NCT05129605
NCT05155501,Clinical TrIAL of Approaches to Prostate cAncer suRgery,Not Applicable,Recruiting,Interventional,Prostate Cancer,Robot-assisted radical prostatectomy (RP); Pelvic fascia-sparing robot-assisted radical prostatectomy (PFS-RP),,Weill Medical College of Cornell University,National Institutes of Health (NIH); National Cancer Institute (NCI),600,2023-05-15,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT05155501
NCT05168618,AtezoCab: A Phase II Study of Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Non-Measurable Disease,Phase 2,Recruiting,Interventional,Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8,Atezolizumab; Cabozantinib S-malate,,University of Utah,National Cancer Institute (NCI),33,2022-03-11,2027-01-05,United States,No,https://clinicaltrials.gov/study/NCT05168618
NCT05413850,"An Open-label, Multicentre, Integrated Phase 1 & 2 Study to Evaluate the Safety, Tolerability, Radiation Dosimetry and Anti-tumour Activity of Lutetium (177Lu) rhPSMA-10.1 Injection in Men With Metastatic Castrate-resistant Prostate Cancer",Phase 1/Phase 2,Recruiting,Interventional,Prostate Cancer; Metastatic Castration-resistant Prostate Cancer; mCRPC; Urogenital Neoplasms; Prostatic Neoplasms; Prostatic Diseases,Lutetium (177Lu) rhPSMA-10.1 Injection; 18F-rhPSMA-7.3 injection (in phase 1 only),,Blue Earth Therapeutics Ltd,PSI CRO,82,2022-07-20,2028-03-31,Netherlands; United States,No,https://clinicaltrials.gov/study/NCT05413850
NCT05498272,A Phase 2 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations (NePtune),Phase 2,Recruiting,Interventional,Prostate Cancer; BRCA1 Mutation; BRCA2 Mutation; Prostatic Adenocarcinoma; High-Risk Cancer,Olaparib; LHRH agonist,,"Rana McKay, MD","AstraZeneca; University of California, San Diego",32,2023-02-01,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT05498272
NCT05519449,"A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer",Phase 1,Recruiting,Interventional,Prostate Cancer; Metastatic Castration-resistant Prostate Cancer; Castration Resistant Prostatic Cancer,JANX007; Darolutamide,,Janux Therapeutics,,272,2022-09-15,2028-12-05,Australia; United States,No,https://clinicaltrials.gov/study/NCT05519449
NCT05534646,"Phase II Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer",Phase 2,Recruiting,Interventional,Castration-resistant Prostate Cancer,Apalutamide; Carotuximab,,"Edwin Posadas, MD","Enviro Therapeutics, Inc.",100,2023-12-27,2027-01-05,United States,No,https://clinicaltrials.gov/study/NCT05534646
NCT05587439,Investigating Hereditary Risk In Thoracic Cancers (INHERIT),,Recruiting,Observational,Lung Cancer; Genetic Disease; Genetic Predisposition; Hereditary Diseases,Data and Specimen Collection,,Dana-Farber Cancer Institute,,500,2023-01-01,2027-11-01,United States,No,https://clinicaltrials.gov/study/NCT05587439
NCT05608694,MRI Screening in Men at High Risk of Developing Prostate Cancer,Not Applicable,Recruiting,Interventional,Prostate Cancer Screening,Prostate MRI,,University of Chicago,,250,2022-03-02,2039-03-01,United States,No,https://clinicaltrials.gov/study/NCT05608694
NCT05625529,Exoluminate Study: Observational Registry Study to Assess Exo-PDAC Assay Performance for Detection of Pancreatic Adenocarcinoma (PDAC) in High-Risk or Clinically Suspicious Patients,,Recruiting,Observational,Pancreas Cancer; Exosomes; Extracellular Vesicles; Pancreatic Neoplasms,,,Biological Dynamics,,1000,2022-12-19,2028-01-01,United States,No,https://clinicaltrials.gov/study/NCT05625529
NCT05689021,Phase 2 Study of CJNJ-67652000 (Niraparib/Abiraterone Acetate Fixed-Dose Combination) and Prednisone for Metastatic Castration-Resistant Prostate Cancer Associated With SPOP Mutation With or Without Homologous Recombination Deficiency,Phase 2,Recruiting,Interventional,Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8,Abiraterone Acetate/Niraparib; Biospecimen Collection; Bone Scan; Computed Tomography; Magnetic Resonance Imaging; Prednisone,,Mayo Clinic,,30,2024-03-05,2027-03-30,United States,No,https://clinicaltrials.gov/study/NCT05689021
NCT05694715,Combination Therapy of Niraparib and Irinotecan in Cancers With Mutations in DNA Repair Genes,Phase 1,Recruiting,Interventional,Metastatic Solid Tumor; BRCA1 Mutation; BRCA2 Mutation; ATM Gene Mutation; PALB2 Gene Mutation,Niraparib; Irinotecan,,"University of California, San Francisco",GlaxoSmithKline,24,2023-05-23,2028-01-31,United States,No,https://clinicaltrials.gov/study/NCT05694715
NCT05722288,"A Randomized, Phase II Clinical Trial of Time-Restricted Eating Versus Nutritional Counseling in Cancer Patients Receiving Radiation or Chemoradiation to Evaluate Its Impact on Toxicity and Efficacy",Phase 2,Recruiting,Interventional,Localized Prostate Carcinoma; Locally Advanced Cervical Carcinoma; Locally Advanced Rectal Carcinoma; Malignant Solid Neoplasm; Recurrent Prostate Carcinoma; Stage I Prostate Cancer AJCC v8; Stage IB Cervical Cancer FIGO 2018; Stage IB2 Cervical Cancer FIGO 2018; Stage II Prostate Cancer AJCC v8; Stage II Rectal Cancer AJCC v8; Stage IIA Cervical Cancer FIGO 2018; Stage IIB Cervical Cancer FIGO 2018; Stage III Prostate Cancer AJCC v8; Stage III Rectal Cancer AJCC v8; Stage IIIA Cervical Cancer FIGO 2018; Stage IIIB Cervical Cancer FIGO 2018; Stage IIIC Cervical Cancer FIGO 2018; Stage IVA Prostate Cancer AJCC v8,Biospecimen Collection; Informational Intervention; Quality-of-Life Assessment; Questionnaire Administration; Short-Term Fasting,,City of Hope Medical Center,National Cancer Institute (NCI),60,2023-01-20,2026-07-20,United States,No,https://clinicaltrials.gov/study/NCT05722288
NCT05765500,RecoverPC: A Phase 2 Study of RElugolix Versus GnRH Agonist Quality of Life (QOL) and Testosterone reCOVERy in Men With Prostate Cancer,Phase 2,Recruiting,Interventional,Prostate Cancer; Prostatic Neoplasms,Relugolix; Leuprolide,,Dana-Farber Cancer Institute,Prostate Cancer Foundation; Pfizer; Myovant Sciences GmbH,110,2024-02-12,2028-01-01,United States,No,https://clinicaltrials.gov/study/NCT05765500
NCT05806515,"S2210 A Phase II Study of Neoadjuvant Carboplatin for Localized, High Risk Prostate Cancer With Germline BRCA1/2 Mutations",Phase 2,Recruiting,Interventional,Prostate Adenocarcinoma; Stage IIIB Prostate Cancer AJCC v8; Stage IIIC Prostate Cancer AJCC v8,Biospecimen Collection; Carboplatin; Chest Radiography; Computed Tomography; Magnetic Resonance Imaging; PSMA PET Scan; Surgical Procedure,,SWOG Cancer Research Network,National Cancer Institute (NCI),44,2024-03-01,2031-06-05,United States,No,https://clinicaltrials.gov/study/NCT05806515
NCT05806814,Pilot Trial to Investigate Immune Response to an Extended Course of Sipuleucel-T Immunotherapy in Patients With Metastatic Castration-resistant Prostate Cancer (OU-SCC-EXCITE),Phase 1,Recruiting,Interventional,Metastatic Castration-Resistant Prostate Cancer (mCRPC),Sipuleucel-T,,University of Oklahoma,Dendreon,13,2023-11-12,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT05806814
NCT06004661,"An Open-label Dosimetry, Biodistribution, Tolerability and Safety Study of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Moderately and Severely Impaired and With Normal Renal Function.",Phase 2,Recruiting,Interventional,Metastatic Castration-Resistant Prostate Cancer (mCRPC),AAA617; 68Ga-PSMA-11,,Novartis Pharmaceuticals,,20,2024-04-04,2026-06-17,France; Germany; Italy; Spain; United States,No,https://clinicaltrials.gov/study/NCT06004661
NCT06029998,A Phase II Study of Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion,Phase 2,Recruiting,Interventional,Metastatic Castration-resistant Prostate Cancer,Bortezomib,,University of Utah,,22,2024-03-11,2028-12-05,United States,No,https://clinicaltrials.gov/study/NCT06029998
NCT06046040,"Phase I, Open-Label Study of Dually Armored Chimeric Antigen Receptor (CAR) T Cells (TmPSMA-02) in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC)",Phase 1,Recruiting,Interventional,Metastatic Castrate-Resistant Prostate Cancer (mCRPC),TmPSMA-02 CAR T Cells,,University of Pennsylvania,Prostate Cancer Foundation,30,2024-01-31,2042-01-31,United States,No,https://clinicaltrials.gov/study/NCT06046040
NCT06049355,EMBark on RAdiation Therapy With a Clinic-based Exercise Program: EXERCISING TOGETHER,Phase 2,Recruiting,Interventional,Breast Carcinoma; Prostate Carcinoma,Exercise Intervention; Biospecimen Collection; Educational Intervention,,OHSU Knight Cancer Institute,Oregon Health and Science University; National Cancer Institute (NCI),400,2024-04-18,2028-09-01,United States,No,https://clinicaltrials.gov/study/NCT06049355
NCT06100705,"A Single Arm Open-label, Phase II Study of Sipuleucel-T With Bipolar Androgen Therapy in Men With Metastatic Castration-resistant Prostate Cancer",Phase 2,Recruiting,Interventional,Metastatic Castration-resistant Prostate Cancer,Testosterone Cypionate; Sipuleucel-T,,Yale University,Dendreon,26,2023-12-20,2028-03-05,United States,No,https://clinicaltrials.gov/study/NCT06100705
NCT06101290,Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER),Not Applicable,Recruiting,Interventional,Prostate Cancer; Oligoprogressive; Urothelial Carcinoma; Renal Cell Carcinoma,Ablative local therapy,,"University of California, Davis",National Cancer Institute (NCI),150,2023-10-05,2031-01-05,United States,No,https://clinicaltrials.gov/study/NCT06101290
NCT06145633,Vorinostat to Augment Response to 177Lutetium-PSMA-617 in the Treatment of Patients With PSMA-Low Metastatic Castration-Resistant Prostate Cancer,Phase 2,Recruiting,Interventional,Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8,Biopsy Procedure; Biospecimen Collection; Bone Scan; Computed Tomography; Fludeoxyglucose F-18; Gallium Ga 68 Gozetotide; Lutetium Lu 177 Vipivotide Tetraxetan; Positron Emission Tomography; Single Photon Emission Computed Tomography; Vorinostat,,Fred Hutchinson Cancer Center,Novartis; Institute for Prostate Cancer Research (IPCR); National Cancer Institute (NCI),15,2024-09-18,2027-12-30,United States,No,https://clinicaltrials.gov/study/NCT06145633
NCT06151223,A Prospective Registry for Patients at High-Risk for Pancreatic Cancer,,Recruiting,Observational,Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma,Bio-specimen Collection: Blood; Bio-specimen Collection: Pancreatic Juice; MRI,,Mayo Clinic,,5000,2021-07-13,2031-07-31,United States,No,https://clinicaltrials.gov/study/NCT06151223
NCT06161506,A Phase II Trial of Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer,Phase 2,Recruiting,Interventional,Urinary Urge Incontinence; Stress Urinary Incontinence; Prostatic Hyperplasia,Elidah Device,,National Cancer Institute (NCI),,41,2024-02-15,2028-03-01,United States,No,https://clinicaltrials.gov/study/NCT06161506
NCT06177171,A Phase I/Ib Study of Olaparib and ASTX727 in BRCA1/2- and HRD-mutated Tumors,Phase 1,Recruiting,Interventional,BRCA1 Mutation; BRCA2 Mutation; BRCA Mutation; PALB2 Gene Mutation; Checkpoint Kinase 2 Gene Mutation; ATM Gene Mutation,Olaparib; ASTX727,,Pamela Munster,National Cancer Institute (NCI),18,2024-02-07,2027-02-28,United States,No,https://clinicaltrials.gov/study/NCT06177171
NCT06190899,"A Phase 1/2, Open-Label, Randomized, Dose Finding and Dose Expansion Study of Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)",Phase 1/Phase 2,Recruiting,Interventional,"mCRPC (Metastatic Castration-resistant Prostate Cancer); Genital Diseases, Male; Urogenital Diseases, Male; Prostatic Disease; Prostatic Neoplasms, Castration-Resistant; Prostate Cancer",Gedatolisib; Darolutamide,,Celcuity Inc,,54,2024-01-01,2027-11-05,France; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06190899
NCT06205316,Randomized Phase III Trial of SBRT Versus Hypofractionated Radiotherapy for Salvage of Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma After Radical Prostatectomy,Phase 3,Recruiting,Interventional,Biochemically Recurrent Prostate Carcinoma; Oligometastatic Prostate Carcinoma; Recurrent Prostate Adenocarcinoma; Stage IIB Prostate Cancer AJCC v8; Stage IIC Prostate Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8,Antiandrogen Therapy; Biospecimen Collection; Hypofractionated Radiation Therapy; Positron Emission Tomography; Stereotactic Body Radiation Therapy; Survey Administration; Magnetic Resonance Imaging,,Mayo Clinic,,118,2024-01-22,2030-01-22,United States,No,https://clinicaltrials.gov/study/NCT06205316
NCT06216249,A Phase 2 Randomized Trial in Patients With Metastatic Castration Resistant Prostate Cancer to Determine the Efficacy of a Flexible Dosing Schedule of Lu-PSMA Treatment up to 12 Cycles Including Potential Treatment Holiday Periods in Comparison to the Standard Fixed Dosing Schedule of Six Cycles Every Six Weeks (FLEX-MRT),Phase 2,Recruiting,Interventional,Prostate Carcinoma; Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8,Computed Tomography; Gallium Ga 68 Gozetotide; Lutetium Lu 177 Vipivotide Tetraxetan; Positron Emission Tomography; PSMA PET Scan; Questionnaire Administration; Single Photon Emission Computed Tomography,,Jonsson Comprehensive Cancer Center,Novartis Pharmaceuticals,90,2024-08-01,2028-12-31,United States,No,https://clinicaltrials.gov/study/NCT06216249
NCT06228053,"A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer, the SYNERGY-201 Trial",Phase 2,Recruiting,Interventional,Metastatic Castration-resistant Prostate Cancer,SX-682; Enzalutamide,,"Syntrix Biosystems, Inc.",National Cancer Institute (NCI),53,2024-11-18,2028-06-30,United States,No,https://clinicaltrials.gov/study/NCT06228053
NCT06242470,"A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumor; Advanced Cancer; Metastatic Cancer; Squamous Cell Carcinoma of Head and Neck; Non Small Cell Lung Cancer; Small-cell Lung Cancer; Bladder Cancer; Sarcoma; Endometrial Cancer; Melanoma; Castration Resistant Prostatic Cancer; Cervical Cancer; Colorectal Cancer; Gastric Cancer; Gastro-esophageal Cancer; Pancreas Cancer; Clear Cell Renal Cell Carcinoma; Hepatocellular Carcinoma; Platinum-resistant Ovarian Cancer; Breast Cancer; Ovarian Cancer; Esophageal Squamous Cell Cancer (SCC),MGC026 Dose Escalation; MGC026 Dose for Expansion,,MacroGenics,,250,2024-03-06,2028-10-05,Australia; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06242470
NCT06253130,"A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation, Dose-optimization, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy in Patients With Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumor,IMP1734,,Eikon Therapeutics,"Impact Therapeutics, Inc.",70,2023-12-11,2026-12-01,Australia; Canada; China; Denmark; France; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT06253130
NCT06288113,Re-Treatment With 177Lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration Resistant Prostate Cancer: A Prospective Phase 2 Trial (RE-LuPSMA STUDY),Phase 2,Recruiting,Interventional,Castration-Resistant Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8,Biospecimen Collection; Computed Tomography; Gallium Ga 68 Gozetotide; Lutetium Lu 177 Vipivotide Tetraxetan; Positron Emission Tomography; Questionnaire Administration; Single Photon Emission Computed Tomography,,Jonsson Comprehensive Cancer Center,Novartis Pharmaceuticals,40,2024-08-01,2027-01-27,United States,No,https://clinicaltrials.gov/study/NCT06288113
NCT06305598,Bipolar Androgen Therapy in Metastatic Castration-Resistant Prostate Cancer (mCRPC),Phase 1,Recruiting,Interventional,Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8,Biopsy; Bone Scan; Computed Tomography; Leuprolide Acetate; Magnetic Resonance Imaging; Survey Administration; Testosterone Cypionate,,Roswell Park Cancer Institute,,14,2024-12-19,2027-12-15,United States,No,https://clinicaltrials.gov/study/NCT06305598
NCT06353386,MK-5684-01A Substudy: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC),Phase 1/Phase 2,Recruiting,Interventional,"Prostatic Neoplasms, Castration-Resistant",Opevesostat; Olaparib; Docetaxel; Cabazitaxel; Fludrocortisone acetate; Dexamethasone; Prednisone,,Merck Sharp & Dohme LLC,"Orion Corporation, Orion Pharma",220,2024-05-20,2029-01-15,Australia; Canada; Chile; Colombia; Denmark; Finland; France; Germany; Ireland; Israel; Italy; Japan; New Zealand; Poland; South Korea; Spain; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06353386
NCT06355336,"Patient Reported Data on Prostate Cancer Diagnosis, Management, and Outcome: Real World Prostate Cancer Registry",,Recruiting,Observational,Prostate Cancer,,,Cincinnati Cancer Advisors,,1000,2024-03-18,2034-03-18,United States,No,https://clinicaltrials.gov/study/NCT06355336
NCT06369610,"Risk Stratified De-Escalated De-Intensified Treatment for High Risk Prostate Cancer Patients Based on Pathologic Criteria, Genetic Score, and Biologic Imaging",Phase 2,Recruiting,Interventional,Oligometastatic Prostate Carcinoma; Prostate Adenocarcinoma,Abiraterone Acetate; Biospecimen Collection; Computed Tomography; Gonadotropin-releasing Hormone Analog; Magnetic Resonance Imaging; Positron Emission Tomography; Questionnaire Administration; Radiation Therapy,,Mayo Clinic,,110,2024-04-22,2027-04-22,United States,No,https://clinicaltrials.gov/study/NCT06369610
NCT06395519,A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies,Phase 1/Phase 2,Recruiting,Interventional,Advanced or Metastatic Solid Tumors; Breast Cancer; Ovarian Cancer; Prostate Cancer; Epithelial Ovarian Cancer; BRCA2 Mutation; ER+ Breast Cancer; Castrate Resistant Prostate Cancer; BRCA1 Mutation; BRCA Mutation; Endometrial Cancer; Colorectal Cancer; Gastric Cancer,ETX-19477,,"858 Therapeutics, Inc.",,120,2024-05-13,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT06395519
NCT06402331,"A Phase 2, Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of FPI-2265 (225Ac-PSMA-I&T) in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)",Phase 2,Recruiting,Interventional,Metastatic Castration-resistant Prostate Cancer,FPI-2265,,Fusion Pharmaceuticals Inc.,,100,2024-03-05,2031-01-23,United States,No,https://clinicaltrials.gov/study/NCT06402331
NCT06402357,Salvage Focal Therapy Via High Intensity Focused Ultrasound (HIFU) in Radiorecurrent Localized Prostate Cancer,Phase 2,Recruiting,Interventional,Prostate Cancer,Focal One high intensity focused ultrasound device,,University of Florida,EDAP-TMS Focal One,25,2025-05-14,2029-08-05,United States,No,https://clinicaltrials.gov/study/NCT06402357
NCT06457919,A Phase 1b/2 Study Evaluating the Activity of Tinengotinib (TT-00420) in Combination With Androgen Receptor Signaling Inhibitors (ARSIs) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC),Phase 1/Phase 2,Recruiting,Interventional,Prostate Cancer,Tinengotinib; abiraterone acetate with prednisone; Enzalutamide,,Memorial Sloan Kettering Cancer Center,TransThera Sciences,50,2024-06-04,2027-06-05,United States,No,https://clinicaltrials.gov/study/NCT06457919
NCT06470243,"A Phase III Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC), Stratified by Aggressive Variant Signature",Phase 3,Recruiting,Interventional,Castration-Resistant Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8,Biospecimen Collection; Bone Scan; Cabazitaxel; Carboplatin; Chest Radiography; Computed Tomography; Magnetic Resonance Imaging; Positron Emission Tomography; Prednisone,,SWOG Cancer Research Network,National Cancer Institute (NCI),528,2024-11-27,2032-04-05,United States,No,https://clinicaltrials.gov/study/NCT06470243
NCT06520345,"A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177Lu) Rosopatamab Tetraxetan in Combination With Standard of Care Versus Standard of Care Alone in Patients With PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously After Androgen Receptor Pathway Inhibitor Treatment",Phase 3,Recruiting,Interventional,Metastatic Castration-resistant Prostate Cancer,177Lu-TLX591; Enzalutamide; Abiraterone; Docetaxel,,Telix Pharmaceuticals (Innovations) Pty Limited,,430,2024-07-26,2030-12-05,Australia; New Zealand; United States,No,https://clinicaltrials.gov/study/NCT06520345
NCT06533644,"A Phase 2a Multicenter, Dose-Escalation and Dose Optimization Study of SYNC-T Therapy SV-102 for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)",Phase 2,Recruiting,Interventional,Metastatic Castration-resistant Prostate Cancer,Partial Oncolysis; SV-102,,"Syncromune, Inc.",,70,2025-05-29,2027-12-14,United States,No,https://clinicaltrials.gov/study/NCT06533644
NCT06538636,Prediction Augmented Screening Initiative,Not Applicable,Not yet recruiting,Interventional,Lung Cancer; Lung Cancer Screening,PCP-Facing Tools; LCS team population management tools,,VA Office of Research and Development,,23520,2026-01-01,2029-09-30,United States,No,https://clinicaltrials.gov/study/NCT06538636
NCT06551324,"A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)",Phase 3,Recruiting,Interventional,Metastatic Castrate Resistant Prostate Cancer (mCRPC),PF-06821497; Docetaxel; Enzalutamide,,Pfizer,,600,2024-10-21,2028-10-29,Argentina; Australia; Brazil; Canada; China; Czechia; France; Germany; Greece; Hungary; Italy; Japan; Netherlands; Poland; Slovakia; South Africa; South Korea; Spain; Sweden; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06551324
NCT06568562,PRO-XL: A Phase II Study of XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer After Progression on Lutetium-177 (177Lu)-PSMA-617,Phase 2,Recruiting,Interventional,Metastatic Castration-resistant Prostate Cancer,XL092,,University of Utah,Exelixis,32,2024-12-09,2028-12-05,United States,No,https://clinicaltrials.gov/study/NCT06568562
NCT06579417,Advanced Restriction Imaging and Reconstruction Technology for Prostate MRI (ART-Pro),,Recruiting,Observational,Prostate Cancer,RSI MRI,,"University of California, San Diego","GE Healthcare; University of California, San Francisco; Massachusetts General Hospital; Weill Medical College of Cornell University; Cambridge University Hospitals NHS Foundation Trust",500,2023-12-15,2029-07-05,United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06579417
NCT06609005,"A Phase 1 and Phase 2, Multi-Center, Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Evidence of Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer",Phase 1/Phase 2,Recruiting,Interventional,Advanced Metastatic Castration Resistant Prostate Cancer,INV-9956,,"Shenzhen Ionova Life Sciences Co., Ltd.",,84,2025-01-23,2028-01-17,China; United States,No,https://clinicaltrials.gov/study/NCT06609005
NCT06615752,A Phase I/II Study to Determine the Safety and Efficacy of a Combination of Green Tea and Quercetin With Docetaxel in Castration-resistant Prostate Cancer Patients,Phase 1/Phase 2,Recruiting,Interventional,Metastatic Castration-resistant Prostate Cancer (mCRPC),green tea and quercetin + docetaxel; Placebo + docetaxel,,Charles Drew University of Medicine and Science,National Institute on Minority Health and Health Disparities (NIMHD); Watts Healthcare Corporation,99,2026-03-05,2029-02-05,United States,No,https://clinicaltrials.gov/study/NCT06615752
NCT06629779,"A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2)",Phase 3,Recruiting,Interventional,Metastatic Castration-Resistant Prostate Cancer,PF-06821497; Placebo; Enzalutamide,,Pfizer,,900,2024-10-22,2028-11-30,Argentina; Brazil; Bulgaria; Canada; Chile; China; Czechia; Denmark; Finland; France; Germany; Greece; Hungary; Italy; Japan; Netherlands; New Zealand; Poland; Slovakia; South Africa; South Korea; Spain; Sweden; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06629779
NCT06631521,Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for High Risk Localized and Locally Advanced Prostate Cancer: A Phase I/Ib Trial,Phase 1,Recruiting,Interventional,Prostate CA; Prostate Cancer (Adenocarcinoma); Prostate Cancer Surgery,Darolutamide; Relugolix; Radical Prostatectomy,,AdventHealth,Bayer; Sumitomo Pharma Switzerland,30,2024-10-22,2026-06-05,United States,No,https://clinicaltrials.gov/study/NCT06631521
NCT06659614,Prostate Tissue Biobank for People at Genetic Risk for Aggressive Disease,,Recruiting,Observational,Prostate Cancer; Genetic Predisposition,,,Abramson Cancer Center at Penn Medicine,,200,2024-01-01,2034-01-05,United States,No,https://clinicaltrials.gov/study/NCT06659614
NCT06691984,"A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy",Phase 3,Recruiting,Interventional,Metastatic Castration-resistant Prostate Cancer,Xaluritamig; Abiraterone; Enzalutamide; Cabazitaxel,,Amgen,,675,2024-12-09,2029-07-30,Australia; Austria; Belgium; Canada; Denmark; France; Germany; Greece; Hong Kong; Italy; Japan; Netherlands; Poland; Singapore; South Korea; Spain; Sweden; Switzerland; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06691984
NCT06710379,A Phase 1a/b Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors,Phase 1,Recruiting,Interventional,Solid Tumors,ADRX-0405,,Adcentrx Therapeutics,,68,2024-12-30,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT06710379
NCT06764485,"A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge",Phase 3,Recruiting,Interventional,Metastatic Castration-resistant Prostate Cancer,BMS-986365; Enzalutamide; Abiraterone; Docetaxel; Predinsone/Prednisolone,,Celgene,,960,2025-03-13,2029-01-19,Argentina; Australia; Austria; Brazil; Canada; Chile; China; Czechia; Denmark; France; Germany; India; Ireland; Italy; Japan; Poland; Puerto Rico; Romania; Slovakia; South Korea; Spain; Sweden; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06764485
NCT06780670,"PSMAcTION: A Phase II/III, Open-label, International, Multicenter, Randomized Study of AAA817 Versus Standard of Care in the Treatment of Adult Participants With PSMA Positive Metastatic Castration-resistant Prostate Cancer Who Progressed on or After [177Lu]Lu-PSMA Targeted Therapy",Phase 2/Phase 3,Recruiting,Interventional,Prostate Cancer,Investigators choice of SoC; AAA817; AAA817; AAA817,,Novartis Pharmaceuticals,,432,2025-02-27,2033-07-19,Australia; Brazil; China; Israel; Japan; Singapore; South Korea; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT06780670
NCT06785636,"A Phase 1b/2a, MultiCenter, Open- Label Study of Pocenbrodib as Monotherapy or in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)",Phase 1/Phase 2,Recruiting,Interventional,"mCRPC (Metastatic Castration-resistant Prostate Cancer); Genital Neoplasms, Male; Urogenital Neoplasms; Urogenital Cancers; Prostatic Diseases; Prostatic Neoplasms; Male Urogenital Diseases; Neoplasms; Neoplasms by Site; Prostate Cancer","Pocenbrodib; Cohort 2A (Pocenbrodib monotherapy), Cohort 2B (Pocenbrodib + abiraterone acetate), Cohort 2C (Pocenbrodib + olaparib), Cohort 2D (Pocenbrodib + 177Lu-PSMA-617",,"Pathos AI, Inc.",Duke University,252,2025-02-07,2029-04-30,United States,No,https://clinicaltrials.gov/study/NCT06785636
NCT06801236,"A Phase 1 Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ACE-232 in Patients With Metastatic Castration-Resistant Prostate Cancer (CRPC)",Phase 1,Recruiting,Interventional,Prostate Cancer (Adenocarcinoma); mCRPC (Metastatic Castration-resistant Prostate Cancer),ACE-232 tablets,,Acerand Therapeutics (Hong Kong) Limited,,67,2025-05-12,2028-08-01,United States,No,https://clinicaltrials.gov/study/NCT06801236
NCT06855277,"A Phase III, Open-label, Multi-center, Randomized Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer",Phase 3,Recruiting,Interventional,Prostate Cancer,AAA817; ARPI; Standard of Care,,Novartis Pharmaceuticals,,940,2025-07-01,2032-11-04,Australia; Brazil; China; Hong Kong; India; Japan; Singapore; South Korea; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06855277
NCT06883838,Enhancing Primary Care Capacity for Cancer Survivorship Care Delivery in Community Health Clinics,Not Applicable,Enrolling by invitation,Interventional,Cancer Survivorship,Survivorship care delivery intervention,,"The University of Texas Health Science Center, Houston",National Cancer Institute (NCI),5584,2025-09-01,2029-05-31,United States,No,https://clinicaltrials.gov/study/NCT06883838
NCT06894511,"A Phase II, Open-label, Multi-Center, Randomized Study Comparing the Combination of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) and Androgen Receptor Pathway Inhibitor (ARPI) vs. Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in First-line Treatment of Patients With Prostate-Specific Membrane Antigen (PSMA)-Positive Progressive Metastatic Castration Resistant Prostate Cancer (mCRPC)",Phase 2,Recruiting,Interventional,Metastatic Castration Resistant Prostate Cancer (mCRPC),AAA617; ARPI: Abiraterone; ARPI: Enzalutamide,,Novartis Pharmaceuticals,,420,2025-09-11,2029-04-09,United States,No,https://clinicaltrials.gov/study/NCT06894511
NCT06906471,"A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS",Phase 1/Phase 2,Not yet recruiting,Interventional,Prostate Cancer; Prostate Cancer (Adenocarcinoma); Fluorescence Imaging,AS1986NS,,"Antelope Surgical Solutions, Inc",,10,2025-12-05,2026-03-05,Taiwan; United States,No,https://clinicaltrials.gov/study/NCT06906471
NCT06960798,Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (Nat-Geno),,Not yet recruiting,Observational,Prostate Cancer,Bio-specimen Collection; Blood Draw,,University of Oklahoma,,150,2026-05-02,2029-06-30,United States,No,https://clinicaltrials.gov/study/NCT06960798
NCT06972628,177Lu-PSMA-617 (Pluvicto) for the Treatment of Patients With Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Super Scan Bone Scan,Phase 2,Recruiting,Interventional,Metastatic Castration-Resistant Prostate Cancer; Prostate Cancer Patients With Bone Metastasis; Prostate Cancer (CRPC); Prostate Cancer; Prostate Cancer Metastatic,Administering Lutetium-177-PSMA-617 (PLUVICTO),,Ebrahim S Delpassand,,30,2025-05-23,2029-04-01,United States,No,https://clinicaltrials.gov/study/NCT06972628
NCT06995898,The Vanguard Study: Testing a New Way to Screen for Cancer,Not Applicable,Recruiting,Interventional,Bladder Carcinoma; Breast Carcinoma; Colorectal Carcinoma; Esophageal Carcinoma; Gastric Carcinoma; Liver Carcinoma; Lung Carcinoma; Malignant Solid Neoplasm; Ovarian Carcinoma; Pancreatic Carcinoma; Prostate Carcinoma,Biospecimen Collection; Device Usage; Electronic Health Record Review; Multi-Cancer Detection Test; Multi-Cancer Detection Test; Questionnaire Administration,,National Cancer Institute (NCI),,24000,2025-06-16,2029-06-30,United States,No,https://clinicaltrials.gov/study/NCT06995898
